Although the company, based in Gaithersburg, Maryland, had never
brought a vaccine to market in its 33-year history, these experts were
optimistic about its technology, which uses moth cells to pump out
crucial molecules at a much faster rate than typical vaccines — a
major advantage in a pandemic.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/the-novavax-story-how-a-struggling-company-won-1-6-billion-to-make-a-coronavirus-vaccine/articleshow/77011213.cms
No comments:
Post a Comment